多巴丝肼联合普拉克索治疗帕金森综合征的效果观察

目的:观察多巴丝肼联合普拉克索治疗帕金森综合征的临床效果。方法:选取收治的40例帕金森综合征患者为研究对象,采用随机数字表法分为研究组和对照组,每组20例。对照组予多巴丝肼治疗,研究组在对照组基础上联合普拉克索治疗,比较两组治疗前后帕金森病评定量表(UPDRS)评分,临床疗效及治疗后运动功能。结果:治疗后,两组UPDRS评分均低于治疗前,且研究组低于对照组,差异均有统计学意义(P<0.05);研究组治疗总有效率为95.00%,高于对照组的60.00%,差异有统计学意义(P<0.05);研究组左手及右手1 min限时运动次数均多于对照组,差异有统计学意义(P<0.05);研究组10 m步行折返起立耗时及转弯耗时均短于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:多巴丝肼联合普拉克索治疗帕金森综合征,可有效改善患者的临床症状,改善预后。

Clinical effects of Levodopa and Benserazide hydrochloride combined with Pramipexole in treatment of Parkinson's syndrome

Objective: To analyze clinical effects of Levodopa and Benserazide hydrochloride combined with Pramipexole in treatment of Parkinson’s syndrome. Methods: 40 patients with Parkinson’s syndrome were selected as the research objects, and divided into control group(n=20) and study group(n=20) by using the random number table method. The control group was treated with Levodopa and Benserazide hydrochloride, while the study group was treated with Pramipexole on the basis of that of the control group. The unified Parkinson’s disease rating scale(UPDRS) score, clinical efficacy, and motor function after the treatment were compared between the two groups. Results: After the treatment, the UPDRS scores of the two groups were lower than those before the treatment;those of the study group were lower than those of the control group;and the differences were statistically significant(P<0.05). The total effective rate in the study group was 95.00%, which was higher than 60.00% in the control group, and the difference was statistically significant(P<0.05). The numbers of 1-minute timed exercise of left hand and right hand in the study group were higher than those in the control group, and the differences were statistically significant(P<0.05). The standing time and turning time for the 10 meters incremental shuttle walking test in the study group were shorter than those in the control group, and the differences were statistically significant(P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05). Conclusions: Levodopa and Benserazide hydrochloride combined with Pramipexole in the treatment of Parkinson’s syndrome can effectively improve the clinical symptoms and improve the prognosis of these patients.